Teon Therapeutics, Inc.

5 articles about Teon Therapeutics, Inc.

• Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (pembrolizumab)

  1/18/2023

  Teon Therapeutics today announced that it has entered into the clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada), a leader in immuno-oncology (IO).

• Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

  11/1/2022

  Teon Therapeutics today announced that the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing.

• Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816

  6/1/2022

  Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816.

• 

  BioSpace Movers & Shakers, March 11

  3/11/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers

• Teon Therapeutics Names Serge Messerlian as CEO

  3/8/2022

  Teon Therapeutics, a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor immuno-oncology therapies in difficult-to-treat cancers, announced the appointment of Serge Messerlian as Chief Executive Officer and member of the board of directors.